Idorsia Pharmaceuticals Ltd: The Lancet and AHA late-breakin

The Lancet reports that in patients with resistant hypertension, aprocitentan was well-tolerated and superior to placebo in lowering blood pressure at week 4 with a sustained effect at week 40Upon approval

Related Keywords

Perth , Western Australia , Australia , United States , Adhaun , Rheinland Pfalz , Germany , Allschwil , Switzerland General , Switzerland , Dublin , Ireland , America , American , Swiss , Andrewc Weiss , Clozelm Aprocitentan , Arthurc Corcoran , Jean Paul Clozel , Markus Schlaich , Martine Clozel , J Physiol Pharmacol , Arterioscler Thromb Vasc , Idorsia Ltd , American Heart Association , Head Of Investor Relations Corporate Communications , European Society Of Hypertension , Hypertension Council , Janssen Biotech Inc , University Of Western Australia Royal Perth Hospitaland , International Society Of Hypertension , High Blood Pressure Research Council Of Australia , Swiss Exchange , Janssen Pharmaceutical Companies Of Johnson , University Of Western Australia Royal Perth Hospital , European Society Of Cardiology , Idorsia Pharmaceuticals Ltd , Late Breaking Science , Scientific Sessions , African American , Royal Perth Hospitaland , North America , Paul Clozel , Chief Executive Officer , Janssen Biotech , Janssen Pharmaceutical Companies , European Society , International Society , Executive Committee , Management Board , Measurement Month , High Blood Pressure Research Council , High Blood Pressure , Folkow Award , Editorial Board , Factor Collaboration , Thromb Vasc Biol , Clin Hypertension , Blood Pressure Lowering Treatment Trialist , Rev Pharmacol , Chief Scientific Officer , Royal Perth Hospital , Vice President , Investor Relations , Pharmaceuticals Ltd , Idorsia , Pharmaceuticals , Lancet , Gate , Breaking , Science , Session , Reports , Significant , Sustained , Effect , Procitentan , Cowering , Flood , Pressure , Patients , Resistant , Hypertension ,